Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
A house with an airy, pleasant floor plan. On closer glance, a tiny walled-off “dead space.” A child’s room with no windows, that too at the far end of the house. The clues are all architectural — but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback